Ardelyx (ARDX) Stock Price, News & Analysis

Company Overview

Ardelyx, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal diseases. The company’s platform is centered on regulating ion transport in the gut, with the goal of addressing conditions that are inadequately served by existing treatments.

Ardelyx’s marketed products include IBSRELA (tenapanor), an oral treatment for adults with irritable bowel syndrome with constipation, and XPHOZAH (tenapanor), a therapy designed to reduce serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response to, or are intolerant of, phosphate binders. Both products are available in the United States.

Founded in 2007, Ardelyx is headquartered in Waltham, Massachusetts. In addition to its commercial products, the company continues to advance an investigational pipeline focused on gastrointestinal and cardiorenal disorders. Ardelyx is led by President and Chief Executive Officer Mike Raab.

Key Stats

• Today's Range: $2.98 to $3.09
• 50-Day Range: $3.00 to $3.83
• 52-Week Range: $2.95 to $8.40
• Volume: 4.61 million shs
• Average Volume: 4.51 million shs
• Market Capitalization: $755.05 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.90
• Consensus Rating: Moderate Buy

Ardelyx Stock Analysis - MarketRank™

Ardelyx scored higher than 61% of companies evaluated by MarketBeat, and ranked 375th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ardelyx has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 9 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Ardelyx has a consensus price target of $13.90, representing about 358.7% upside from its current price of $3.03.

Amount of Analyst Coverage

Ardelyx has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ardelyx are expected to grow in the coming year, from ($0.20) to $0.24 per share.

Price to Book Value per Share Ratio

Ardelyx has a P/B Ratio of 4.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.81% of the float of Ardelyx has been sold short.

Short Interest Ratio / Days to Cover

Ardelyx has a short interest ratio ("days to cover") of 6.48.

Change versus previous month

Short interest in Ardelyx has recently increased by 9.25%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ardelyx does not currently pay a dividend.

Dividend Growth

Ardelyx does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.00

News Sentiment

Ardelyx has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for Ardelyx this week, compared to 6 articles on an average week.

Search Interest

Only 5 people have searched for ARDX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

4 people have added Ardelyx to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Ardelyx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $486,588.00 in company stock.

Percentage Held by Insiders

5.30% of the stock of Ardelyx is held by insiders.

Percentage Held by Institutions

58.92% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 11/02/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ARDX
• CIK: 1437402
• Web: www.ardelyx.com
• Phone: (510) 745-1700
• Fax: 510-745-0493
• Employees: 489
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Ardelyx: $13.90
• High Price Target: $19.00
• Low Price Target: $9.00
• Potential Upside/Downside: +358.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$61.60 million
• Net Margins: -12.35%
• Pretax Margin: -12.30%
• Return on Equity: -36.00%
• Return on Assets: -10.77%

Debt

• Debt-to-Equity Ratio: 1.69
• Current Ratio: 3.34
• Quick Ratio: 3.15

Sales & Book Value

• Annual Sales: $407.32 million
• Price / Sales: 1.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.69 per share
• Price / Book: 4.39

Miscellaneous

• Outstanding Shares: 249,190,000
• Free Float: 235,981,000
• Market Cap: $755.05 million
• Optionable: Optionable
• Beta: 0.68